

UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

SLAYBACK PHARMA LLC

Petitioner

v.

SUMITOMO DAINIPPON PHARMA CO., LTD

Patent Owner

Patent No. 9,815,827
Filing Date: August 28, 2014
Issue Date: November 14, 2017

Title: AGENT FOR TREATMENT OF SCHIZOPHRENIA

Case No. IPR2020-01053

PETITION FOR *INTER PARTES* REVIEW

TABLE OF CONTENTS

	<u>Page</u>
LISTING OF EXHIBITS.....	8
I. INTRODUCTION	13
A. Summary of Grounds.....	14
II. U.S. PATENT 9,815,827.....	14
A. Overview.....	14
1. Specification of the ‘827 Patent	14
2. Excerpts from ‘827 Patent Prosecution History.....	15
a. Provisional Application.....	15
b. Priority Application	16
c. ‘827 Patent Application.....	17
III. CLAIM CONSTRUCTION	18
A. “a patient” and “the patient”	18
B. “treating a patient with an antipsychotic”	20
C. “manic depressive psychosis”	21
D. “a pharmaceutical composition comprising...a sole active ingredient” ..	22
IV. CLAIMS 1-75 ARE UNPATENTABLE	23
A. Person of Skill in the Art (POSA)	23
B. Manic Depressive Claims Cannot Claim Priority Before August 28, 2014 Filing Date of ‘827 Patent Application	23
1. Manic Depressive Claims.....	24
a. Claims 8-18.....	24
b. Claims 25-28, 30-31 and 33-39.....	24
c. Claims 40-44, 46 and 48-55	24
d. Claims 56-60, 62, 64, 66, 67, 69, 71, 73 and 75	25
2. Priority Application Lacks Written Description of the Manic Depressive Claims.....	25
a. Law of Written Description.....	25
b. The Priority Application Does Not Contain Written	

Description of Using Lurasidone or its Salts to Treat Manic Depressive Psychosis.....		26
C. Ground 1: Latuda® Information Anticipates the Manic Depressive		
Claims.....		31
1. treating manic depressive psychosis in a patient		32
2. administering orally.....		32
3. lurasidone or a pharmaceutically acceptable salt thereof.....		33
4. at a dose of from 20 to 120 mg/day.....		33
5. no clinically significant weight gain		33
6. hydrochloride.....		34
7. no weight gain after six weeks of administration		34
8. detecting a weight gain after six weeks of administration.....		34
9. without concurrently administering another antipsychotic medication.....		35
10. treating a patient with an antipsychotic.....		35
11. sole active ingredient.....		35
12. tablet		35
13. without a weight gain		36
14. once daily administration		36
15. amounts in composition (for once daily administration)		37
D. Ground 2: Manic Depressive Claims Obvious Over Latuda® Information and Loebel		38
1. Prior Art for Ground 2.....		38
a. Latuda® Information.....		38
b. Loebel		39
c. June 2013 Press Release.....		40
d. Latuda Label 2012.....		40
e. Latuda Label July 2013		40
2. Ground 2 Limitation By Limitation Analysis		41
a. treating manic depressive psychosis in a patient.....		41
b. administering orally.....		41
c. lurasidone or a pharmaceutically acceptable salt thereof..		42
d. at a dose of from 20 to 120 mg/day.....		42
e. no clinically significant weight gain		42

f.	hydrochloride.....	43
g.	no weight gain after six weeks of administration.....	43
h.	detecting a weight gain after six weeks of administration .	44
i.	without concurrently administering another antipsychotic medication	45
j.	treating a patient with an antipsychotic.....	45
k.	sole active ingredient.....	46
l.	tablet	46
m.	without a weight gain	46
n.	once daily administration	47
o.	amounts in composition (for once daily administration) ...	48
E.	Ground 3: Claims 1-75 Obvious Over Saji Patent.....	50
1.	Prior Art for Ground 3.....	50
a.	Saji Patent EX-1009	50
b.	Saji Amendment	50
c.	Olanzapine 2001	51
d.	Horisawa.....	51
e.	Allison and Wetterling	53
f.	ICH-4.....	54
2.	Ground 3 Limitation By Limitation Analysis.....	54
a.	treating manic depressive psychosis in a patient.....	54
b.	administering orally.....	54
c.	lurasidone or a pharmaceutically acceptable salt thereof...55	
d.	at a dose of from 20 to 120 mg/day.....	55
e.	no clinically significant weight gain	55
f.	hydrochloride.....	56
g.	no weight gain after six weeks of administration.....	56
h.	detecting a weight gain after six weeks of administration .	57
i.	without concurrently administering another antipsychotic medication	57

j.	treating a patient with an antipsychotic.....	58
k.	sole active ingredient.....	58
l.	tablet.....	58
m.	without a weight gain.....	59
n.	once daily administration.....	59
o.	amounts in composition (for once daily administration) ...	60
p.	treating schizophrenia.....	61
q.	BPRS.....	61
V.	MANDATORY NOTICES.....	644
A.	Real Parties-In-Interest.....	644
B.	Related Matters.....	644
C.	Identification of Counsel and Service Information.....	64
VI.	CERTIFICATION UNDER 37 C.F.R. § 42.24(D).....	655
VII.	GROUND FOR STANDING.....	655
VIII.	STATEMENT OF PRECISE RELIEF REQUESTED FOR EACH CLAIM CHALLENGED.....	65
IX.	CONCLUSION.....	666

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.